bioAffinity reports April CyPath Lung unit sales jump nearly 300% year over year
PUBT · 05/12 13:15
Share
Listen to the news
- bioAffinity Technologies reported record monthly unit sales for CyPath Lung in April 2026, based on preliminary unaudited data.
- CyPath Lung unit sales rose nearly 300% from April 2025, exceeding internal projections.
- Growth was attributed to accelerating physician adoption, expansion of ordering sites, and deeper integration into clinical workflows for lung cancer risk assessment and pulmonary nodule management.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605120915BIZWIRE_USPR_____20260512_BW770887) on May 12, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending